Yanelda de los Angeles García

Dr. Yanelda de los Angeles García

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Seminars in Oncology
Verified
Journal Article
Closed access
IBIraldo Bello-Rivero
Iraldo Bello-Rivero
YGYanelda de los Angeles García
Yanelda de los Angeles García
YDYaquelin Duncan-Roberts
Yaquelin Duncan-Roberts
DVDania Vazquez-Blomquistc
Dania Vazquez-Blomquistc
HSHector Santana-Milian
Hector Santana-Milian
MRMargarita Rios-Cabrera
Margarita Rios-Cabrera

30 July 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LALorenzo Anasagasti-Angulo
Lorenzo Anasagasti-Angulo
YGYanelda de los Angeles García
Yanelda de los Angeles García
SBSilvia Barcelona-Perez
Silvia Barcelona-Perez
PLPedro Lopez-Saura
Pedro Lopez-Saura
IBIraldo Bello-Rivero
Iraldo Bello-Rivero
Background: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery. Interferons (IFN) may provide a non-surgical approach to the management of these tumors. The aim of this work was to evaluate the effect of a formulation containing IFNs-α and -γ in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC). Methods: Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks. They had been previously treated with surgery and/or radiotherapy or chemotherapy. Thirteen weeks after the end of treatment, the original lesion sites were examined for histological evidence of remaining tumor. Results: Sixteen elder (median 70 years-old) patients were included. They beared 12 BCC and 4 SCSC ranging from 1.5 to 12.5 cm in the longest dimension. At the end of treatment 47% CR (complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were obtained. None of the patients relapsed during the treatment period. The median duration of the response was 38 months. Only one patient with complete response had relapsed until today. Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated. Conclusion: The peri- and intralesional combination of IFNs-α and -γ was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients. This is the first report of such treatment in patients with advance non-melanoma skin cancer. The encouraging result justifies further confirmatory trials. Trial registration: Current Controlled Trials RPCEC00000052.

7 December 2016 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
IGIdrian García-García
Idrian García-García
IHIgnacio Hernández-González
Ignacio Hernández-González
ADAlina Díaz-Machado
Alina Díaz-Machado
CDCarlos Alberto González Delgado
Carlos Alberto González Delgado
SPSonia Pérez-Rodríguez
Sonia Pérez-Rodríguez
CGCIGB-128-A Study Group
CIGB-128-A Study Group
More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. This could be achieved by combining IFN alpha and IFN gamma. The aim of this work was to characterize the pharmacokinetics and pharmacodynamics of a novel formulation containing a co-formulated combination of IFNs alpha-2b and gamma (CIGB-128-A). A group of nine healthy male subjects received intramuscularly 24.5 × 106 IU of CIGB-128-A. IFN concentrations were evaluated for 48 h. Serum neopterin, beta2-microglobulin (β2M) and 2′–5′ oligoadenylate synthetase (2′–5′ OAS), classical IFN-inducible serum markers, were measured during 192 h by enzyme immunoassay and body temperature was used as pharmacodynamic variable as well. Concerning pharmacokinetics, serum IFNs’ profiles were better fitted to a mono-compartmental model with consecutive zero order and first order absorption, one bioavailability value. No interferences by simultaneous administered IFNs were observed in their typical similar systemic profiles. Neopterin and β2M time profiles showed a delay that was efficiently linked to pharmacokinetics by means of a zero order absorption rate constant. Neopterin level was nine-fold higher than initial values, 48 h post-administration, an increment not described before. At this time, mean serum β2M peaked around the double from baseline. Serum concentrations of the enzyme 2′–5′ OAS was still elevated on the 8 day post-injection. The formulation was well tolerated. Most frequent adverse reactions were fever, headache, arthralgia and lymphopenia, mostly mild. The administration of co-formulated IFN alpha-2b and IFN gamma likely provides improved pharmacodynamic properties that may be beneficial to treat several malignancies. Cuban Public Registry of Clinical Trials RPCEC00000118 , May 24, 2011.

30 March 2005 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
PDF file
FHFrancisco Hernández-Bernal
Francisco Hernández-Bernal
IGIdrian García-García
Idrian García-García
CGCarlos A. González-Delgado
Carlos A. González-Delgado
CVCarmen Valenzuela-Silva
Carmen Valenzuela-Silva
RSRamón Soto-Hernández
Ramón Soto-Hernández
PLPedro López-Saura
Pedro López-Saura

28 December 2012 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
YGYanelda de los Angeles García
Yanelda de los Angeles García
IGIdrian García-García
Idrian García-García
SCSonia E Collazo-Caballero
Sonia E Collazo-Caballero
ESEgla E Santely-Pravia
Egla E Santely-Pravia
ACAlieski Cruz-Ramírez
Alieski Cruz-Ramírez
IBIraldo Bello-Rivero
Iraldo Bello-Rivero
Background: The synergistic combination of interferon (IFN) alpha-2b and IFN gamma results in more potentin vitrobiological effects mediated by both IFNs. The aim of this investigation was to evaluate by first time the pharmacokinetics and pharmacodynamics of this combination in patients with mycosis fungoides.Methods: An exploratory, prospective, open-label clinical trial was conducted. Twelve patients, both genders, 18 to 75 years-old, with mycosis fungoides at stages IB to III, were eligible for the study. All of them received intramuscularly a single high dose (23 × 106 IU) of a novel synergistic IFN mixture (HeberPAG®) for pharmacokinetic and pharmacodynamic studies. Serum IFN alpha-2b and IFN gamma concentrations were measured during 96 hours by commercial enzyme immunoassays (EIA) specific for each IFN. Other blood IFN-inducible markers and laboratory variables were used as pharmacodynamics and safety criteria.Results: The pharmacokinetic evaluation by EIA yielded a similar pattern for both IFNs that are also in agreement with the well-known described profiles for these molecules when these are administered separately. The average values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL, half-life (t1/2): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma, respectively. The pharmacodynamic variables were strongly stimulated by simultaneous administration of both IFNs: serum neopterin and beta-2 microglobulin levels (β2M), and stimulation of 2’-5’ oligoadenylate synthetase (OAS1) mRNA expression. The most encouraging data was the high increment of serum neopterin, 8.0 ng/mL at 48 h, not been described before for any unmodified or pegylated IFN. Additionally, β2M concentration doubled the pre-dose value at 24–48 hours. For both variables the values remained clearly upper baseline levels at 96 hours.Conclusions: HeberPAG®possesses improved pharmacodynamic properties that may be very useful in the oncologic setting. Efficacy trials can be carried out to confirm these findings.Trial registration: Registro Público Cubano de Ensayos ClínicosRPCEC00000130

5 January 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MTMaría Eugenia Toledo-Romani
María Eugenia Toledo-Romani
MGMayra García-Carmenate
Mayra García-Carmenate
LVLeslyhana Verdecia-Sánchez
Leslyhana Verdecia-Sánchez
SPSuzel Pérez-Rodríguez
Suzel Pérez-Rodríguez
MRMeybis Rodriguez-González
Meybis Rodriguez-González
SGSOBERANA Research Group
SOBERANA Research Group
Background We report results of immunogenicity, safety and reactogenicity of SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. Method This phase IIb trial was designed as parallel, multicentre, adaptive, double blind, randomized and placebo-controlled. Subjects (N=810) aged 19-80 years were randomized to receive two doses of the recombinant SARS CoV-2 receptor binding domain (RBD) conjugated to tetanus toxoid (SOBERANA 02) and a third dose of dimeric RBD (SOBERANA Plus) 28 days apart; two production batches of active ingredient of SOBERANA 02 were evaluated. Primary outcome was the percentage of seroconverted subjects with ≥4-fold the anti-RBD IgG concentration. Secondary outcomes were safety, reactogenicity and neutralizing antibodies. Results Seroconversion rate in vaccinees was respectively 76.3 and 96.8% after two or three doses, compared with 7.3% in placebo group. Anti-RBD IgG increased significantly after first and second dose of SOBERANA 02 respect to placebo group; and the third dose with SOBERANA Plus boosts the response compared to the second dose. Neutralizing IgG antibodies were detected against D614G and VOCs α, β and δ. Specific and functional antibodies were detected at least until 7-8 months after the third dose. The frequency of serious adverse events (AEs) associated with vaccination was very low (0.1%); with only one serious AE consistent with vaccination. Local pain was the most frequent AE. Conclusions Two doses of SOBERANA 02 were well tolerated, safe an immunogenic in adults aged 19-80 years old. The heterologous combination with a third dose of SOBERANA Plus increased neutralizing antibodies, detectable 7-8 months after finishing the vaccination schedule. Trial registry https://rpcec.sld.cu/trials/RPCEC00000347